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Exploiting the neoantigen 
landscape for immunotherapy of 
pancreatic ductal adenocarcinoma
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Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited 
success. It has been postulated that a low mutation load may lead to a paucity of T cells within the 
tumor microenvironment (TME). However, it is also possible that while neoantigens are present, 
an effective immune response cannot be generated due to an immune suppressive TME. To discern 
whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic 
profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC 
samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced 
activation signature; and (c) markers of efficient antigen presentation are associated with a reduced 
signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence 
of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify 
iNOS as a potential mediator of immune suppression that might be actionable using pharmacological 
avenues.
Pancreatic ductal adenocarcinoma (PDAC) will be diagnosed in approximately 53,000 patients in the United 
States in 2016, and an estimated 41,000 will die from its effects1. One the most lethal forms of cancer, the overall 
five year survival rate of patients with PDAC is only 8%. A large proportion of patients present with advanced and 
metastatic disease at initial diagnosis and are presented with treatment options restricted to cytotoxic chemo-
therapies which extend life by no more than a few months2. A significant amount of research aims to identify new 
therapeutic agents and effective combinations of existing therapies to generate more options for PDAC patients at 
all stages of disease, but these efforts have not yet significantly improved patient survival3.
Immunotherapy has proven to be a promising therapeutic avenue for numerous solid cancers, such as mela-
noma and lung cancers. Cancers express tumor-associated antigens (TAAs), short peptides of 8–12 amino acids, 
on human leukocyte antigen (HLA) molecules at the cell surface. TAAs can be neoantigens, arising as a result of 
processed cancer-specific mutant peptides, or aberrant self-antigens like mesothelin or epidermal growth fac-
tor receptor (EGFR), due to overexpression of oncogenic proteins. Neoantigens usually evoke a more robust 
T-cell response due to the lack of thymic elimination of autoreactive T cells, which is known to exist against 
self-antigens. Not surprisingly, cancers with higher mutation loads also harbor higher numbers of neontigens 
presented on HLA molecules, thereby leading to an influx of greater numbers of TAA-reactive T cells. For exam-
ple, melanomas demonstrate an average of 511 coding mutations according to Cancer Genome Atlas (TCGA) 
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data, and are characterized by large numbers of tumor-infiltrating lymphocytes (TILs)4. Another example of this 
correlation between mutational load and TILs is observed in cancers with microsatellite instability (e.g., Lynch 
syndrome), where large numbers of TILs are observed in cases that bear thousands of neoantigens5.
Clinical trials of immune checkpoint inhibitors (anti-CTLA-4) and cancer vaccines (e.g. MUC1, GVAX), 
although well tolerated and able to generate an immune response, have demonstrated only limited impact on 
overall patient survival in PDAC6–11. Data from animal models of PDAC suggest a phenomenon of T-cell exclu-
sion from the immediate tumor microenvironment (TME), which might be the basis for recalcitrance to check-
point inhibitor therapy (including, anti-PD-1 and anti-CTLA-4)12. A possible reason for this T-cell exclusion 
may be the relatively low mutational load observed in PDAC (we identified an average of 62 coding mutations 
in our recent study on genomic analysis of PDAC13). An alternative explanation for the resistance of PDAC to 
immunotherapy may be that while both neoantigens and corresponding TAA-reactive CD8+ TILs exist in PDAC, 
there is profound immune suppression that leads to ineffective T-cell activation and immune rejection. Such 
functional immune suppression, despite an effector T-cell influx, might be caused by the presence of regulatory 
T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) and other 
inhibitory cytokines like TGFbeta and IL-10, all of which have been reported in the PDAC milieu14,15. In such 
cases, removal of immune suppression barriers, such as depletion of myeloid cells16, or artificially “boosting” the 
immune response through TAA-targeted vaccines or adoptively transferring T cells could enable overcoming 
tolerance17,18. In line with this, it has recently been shown that T cells engineered against Mesothelin, a surface 
antigen present on mesothelial cells, can cause tumor lysis and increased survival in PDAC patients19.
The objective of this study was to use large publicly available datasets of PDAC – specifically, TCGA and the 
Australian Pancreatic Cancer Genome Initiative, Australian contribution to the International Cancer Genome 
Consortium (ICGC) – to comprehensively decipher the neoantigen landscape of PDAC, and to determine how 
this landscape correlates with the measurable immune response signatures within the TME. For the first time, 
availability of deeply sequenced transcriptomes derived from “whole tissue” human PDAC samples (versus cell 
line or xenograft-derived RNA profiles) allows us to address questions related to both cancer cell specific neo-
antigens, as well as the host immune response, in this disease. Auditing the neoantigen landscape of PDAC is 
significant, given the possibility of identifying recurrent epitopes that might be presented across multiple tumors 
that share HLA subtypes. This finding, in turn, could enable the development of shared TAA-targeted vaccines 
or adoptive cellular approaches and to augment the possibility of immune rejection, as previously mentioned. An 
additional deliverable of our approach is to identify putative mediators of immune suppression within the TME, 
which might be impeding an effective T-cell response in tumors with an otherwise discernible TIL influx. Indeed, 
as further elaborated below, we find that PDAC cases, while lacking the neoantigen diversity of melanomas, do 
present candidate neoantigens, including ones expected to have efficient presentation by HLA class I molecules. 
Further, in contrast to some prior reports in animal models, we find robust TIL signatures within the TME, but 
a reduced expression of activation associated transcripts, suggesting a functional immune suppression as the 
dominant outcome. Finally, we identify some potential mediators of this immune suppression that might be targ-
etable using pharmacological agents, possibly in combination with immune therapies to overcome the profound 
recalcitrance to immune response in PDAC.
Results
Nearly all PDAC cases express candidate neoantigens. A database was constructed of all possible 
neopeptides that are predicted to bind to, and be presented by, a given patient’s HLA molecules. The landscape 
of neoantigens (Fig. 1) in PDAC is not as vast as in skin cutaneous melanoma (SKCM): the TCGA (n = 133) and 
also the ICGC (n = 88)20 PDAC cases have significantly fewer predicted neoantigens than the TCGA SKCM 
tumors (n = 344). The predicted number of neoantigens varied from four to four thousand in PDAC samples. In 
SKCM the predicted potential neoantigen count was from eleven (which is considered very low in SKCM) to 14 
thousand, and this was significantly higher than in PDAC (p < 0.001 for both PDAC data sets vs. SKCM). Notably, 
KRAS codon 12 mutations are the most common genetic alteration in this cancer, and indeed, the corresponding 
mutant peptide was predicted to generate likely immunogenic21 neoantigens for most of the TCGA and ICGC 
patients bearing this mutation (Supplementary Fig. 1). Thus, this mutant epitope could potentially be used as one 
target of an “off-the-shelf ” vaccine or adoptively transferred T cells, although we do not have functional data on 
the avidity of the corresponding T-cell receptor (TCR). Other examples of mutations that we found to generate 
potential neoantigens for multiple patients were KRAS Q61H, TP53 R273N, TP53 R282W, MT-ND4 A318T, 
FCGBP A2493V, RBM12 P693S, and RET A1019V. Although the frequency of shared neoantigens from these 
mutations is low, these targets may be appropriate for a few percent of patients (Supplementary Fig. 2).
PDAC is characterized by robust TILs, but absence of T-cell activation signature. We analyzed the 
expression of LCK, a T-cell marker, and several genes related to T-cell function and subset (CD8A, IFNG, PRF1, 
GZMA, GZMB, CTLA4, PD-1, PD-L1, IDO1, IDO2, ARG1, LAG3, CD160, KLRG1) as well as Treg (FOXP3, 
CD25/IL2RA), and MDSC (CD11b, CD33, CD14, CD15) markers in TCGA tumor and Genotype-Tissue 
Expression (GTEx)22 normal tissues. We found very high PDAC LCK expression (Fig. 2a) indicating a robust 
TILs presence in PDAC. LCK expression in PDAC was not statistically significantly different from SKCM in the 
TCGA (Fig. 2a). In contrast, interferon gamma (IFNγ) expression was low (Fig. 2b) suggesting reduced T-cell 
activity. Effector T-cell markers and genes related to checkpoint blockade also showed lower expression in PDAC 
than in more immunogenic tumors like skin cutaneous melanoma, and higher expression than in normal pan-
creas (Supplementary Fig. 3, sample level figures and heatmap) further reinforcing the presence of less-activated 
T cells. CD8A, PRF1, GZMB, CTLA4, PD-1, LAG3, and CD160 expression was significantly lower in PDAC 
than in SKCM (p < 0.001 for each) similarly to the KLRG1 T-cell senescence marker (p < 0.05), but interestingly 
GZMA, IDO2, and ARG1 were significantly higher in PDAC than in SKCM (p < 0.001, p < 0.5, p < 0.001, 
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respectively). The Treg transcription factor FOXP3 was significantly lower (p < 0.01), while CD25 (IL2RA) was 
significantly higher (p < 0.0001) in PDAC (n = 147) than in skin cutaneous melanoma (n = 472) indicating that 
CD25 is expressed in PDAC by non-regulatory T cells as well (Supplementary Fig. 3). HLA-A and the HLA 
expression regulator NLRC523 showed high expression levels (Supplementary Fig. 3) further demonstrating that 
antigens can be presented in PDAC.
Negative correlation between antigen presentation and immune cytotoxic activity. Clustering 
of expressions of cytotoxicity immune markers24, as well as antigen presentation-related genes showed a negative 
correlation between antigen presentation and immune activity (Fig. 3). High expression of HLA class I and class 
II genes were associated with low expression of cytotoxicity markers (CD8A, IFNG, PRF1, GZMA, GZMB) while 
Figure 1. The neoantigen landscape of pancreatic ductal adenocarcinoma and skin cutaneous melanoma. 
Binding affinity of neopeptides is shown for PDAC samples in the TCGA (a) and ICGC (b) projects for affinity 
< 500 nM neopeptides. Strong binder (< 50 nM) neopeptides are highlighted with green color. TCGA skin 
cutaneous melanoma neopeptides are presented similary (c). Red boxes represent the quartile below the median 
neopeptide binding affinity, while pink boxes highlight quartiles above the median binding affinity.
Figure 2. T cells are present but inactive in PDAC. Expression levels of LCK T-cell marker (a) and interferon 
gamma which plays a central role in immune system function (b) are shown on the y axis for 30 tumor tissue 
types (grey, red: pancreatic cancer) and normal tissues (normal pancreas, spleen, whole blood). Dark and light 
grey boxes represent the two quartiles around the median expression.
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low antigen presentation was coupled with higher immune activity in both the TCGA (Fig. 3a) and ICGC PDAC 
data sets (Fig. 3b). We also observed similar tendencies in the SKCM data set (Fig. 3c).
High mutation load is associated with fewer cytotoxic T cells. Similarly to how antigen 
presentation-related gene expressions inversely correlated with immune cytotoxicity, mutation load also showed 
a negative correlation with cytotoxic immune markers (Fig. 4a). Notably, CD8A expression exhibited a negative 
correlation with mutation load in the TCGA (p < 0.01) and in the ICGC (p = 0.0817) PDAC data sets. Most of 
the class II (but not class I) antigen presentation and effector T-cell markers correlated negatively with muta-
tion load in the TCGA pancreatic data set, and a few of them in the ICGC cohort as well. In line with this, we 
observed a significantly better (p < 0.05) overall survival for TCGA pancreatic patients having fewer mutations 
(Supplementary Fig. 4). Contrary to PDAC, skin cutaneous melanoma mutation and neoantigen load showed 
positive correlations with class I antigen presentation (Fig. 4a). LCK and HLA-A displayed similarly positive cor-
relations in both cancers with all markers except NOS2 (iNOS), which was observed only in the two PDAC data 
sets. Clearly, NOS2 mRNA showed a positive correlation with antigen presentation and immune markers only 
in PDAC (Fig. 4a, last row) supporting that it plays a role in PDAC immunosuppression as the T-cell numbers 
increase in the tumor.
We have also correlated gene program (GP) scores13, which represent distinct biological processes, with muta-
tion and neoantigen load. GP6, GP7 and GP8 scores (which represent immune programs) negatively correlated 
with mutation load (Fig. 4b). Interestingly, we found positive correlations between mutation and neoantigen load 
with GP4 (proliferation) and GP5 (activated MYC pathways, autophagy, and RNA processing) programs.
Figure 3. Gene expressions related to antigen presentation and cytotoxic activity are negatively correlated. 
Antigen presentation (red bar: class I-related - HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, NLRC5, LMP2, 
and LMP7, orange bar: class II-related - HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, and HLA-DPA1) and 
immune cytotoxicity gene expression (blue bar, CD8A, GNLY, GZMA, GZMB, GZMH, GZMK, IFNG, and 
PRF1) clustering shows two dominant cluster pairs in the TCGA (a) and ICGC (b) PDAC data sets, and also 
in SKCM (c). Low class I and/or class II antigen presentation (green in heat map) is associated with high (red 
in heat map) expression of cytotoxicity markers, while high antigen presentation correlates with low cytotoxic 
activity.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:35848 | DOI: 10.1038/srep35848
NOS2 (iNOS) is overexpressed in PDAC and is a potential target to augment immune 
response. NOS2 was the only immune suppression indicator which showed PDAC-specific correlations with 
immune markers, therefore we further characterized its role in PDAC. NOS2 expression in PDAC (n = 147) 
was significantly higher than in normal pancreas (n = 171) (p < 0.0001), while the pancreatic ductal adenocar-
cinoma and skin cutaneous melanoma (n = 472) expressions were not significantly different (Fig. 5a). NOS2 
was expressed in the Cancer Cell Line Encyclopedia (CCLE) pancreatic cancer cell lines (Supplementary Fig. 5), 
therefore it is not only present in stromal and immune cells but also in the tumor cells. To show that NOS2 is 
functionally important in PDAC tumor cells we evaluated the drug response data of the CCLE and found that 
multiple drugs are more or less effective depending on the expression of NOS2 (Fig. 5b). Notably, CDK4/6 and 
c-MET inhibitors showed negative correlations between NOS2 expression and drug EC50 values.
Discussion
We have conducted a systematic study to identify novel target antigens for PDAC immunotherapy. In the process, 
we have expanded and refined the repertoire of potential targetable PDAC neoantigens, identifying mutated 
peptides that could be used to maximize destruction of tumors with minimal to no damage to healthy tissues. We 
believe that a significant percentage of pancreatic cancer patients may benefit from immunotherapy approaches 
tailored to and targeting these PDAC-specific antigens. The most promising neoantigen candidate is from KRAS 
Figure 4. Mutation load in PDAC negatively correlates with T-cell activity. Spearman’s rank correlation 
coefficients showing how mutation load (first row), neoantigen load (second row), and LCK, HLA-A, and NOS2 
(rows 3–5) correlate with gene expressions related to class I and II antigen presentation, cytotoxic activity, 
immune checkpoints, Treg, and MDSC cells (panel a). Gene program scores related to proliferation, activated 
MYC pathways, autophagy, and RNA processing show positive, while B cell, CD4+ T cell and TLR signaling, 
antigen presentation, and CD8+ T cell signaling show negative correlations (panel b). Only p < 0.1 correlations 
are shown.
Figure 5. Expression and drug response associations of NOS2/iNOS. Gene expressions are shown on the y 
axis for normal pancreas, PDAC, and skin cutaneous melanoma (a). PDAC expression is significantly higher 
compared to normal pancreas (p < 0.0001). Pearson’s correlation coefficients of NOS2 gene expression and drug 
EC50 values (b) are presented as indicated by the color scale (green: negative, red: positive correlation).
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codon 12 mutations. It was recently shown that T-cell receptors (TCRs) that are reactive to KRAS G12V and 
G12D neoantigens can be isolated21.
Our results indicate that T cell-based immunotherapy approaches could be feasible for most patients with a 
KRAS G12 mutation. Other mutations may also give rise to similarly immunogenic mutations, but these would 
only be suitable for a few percent of patients. Our goal was to characterize the neoantigen universe of PDAC, 
however, it also needs to be determined which neopeptides are actually presented on HLA molecules of which 
patients. To do this, tumor-associated peptides can be eluted from MHC class I HLA-A, HLA-B, and HLA-C 
molecules isolated from PDAC tumor samples25,26.
In addition to demonstrating the availability of neoantigens, we have also shown that higher mutation load 
and a higher expression of genes involved in antigen presentation are associated with an expression profile that 
implies less cytotoxic activity. This is surprising because high HLA and neoantigen expression is associated with 
better prognosis in other cancers27. Although T cells are present in PDAC, they do not show a sufficient activity 
presumably due to immune suppression28. This mechanism also potentially includes immune-escape mechanisms 
such as decreasing the efficiency of neoantigen presentation in tumors where the cytotoxic T-cell infiltration is 
higher. Nevertheless, our results suggest that overexpression of the immunosuppressive inducible NO synthase 
(iNOS/NOS2) is associated with higher levels of antigen presentation and poor cytotoxic T-cell capability.
Many human cancers express inflammatory molecules that lead to an intrinsic pro-oxidant environment in 
the cancer cell, as well as potentiating a microenvironment that drives immune escape and resistance to apoptosis, 
one of which is iNOS. The concentration of NO, produced by iNOS, influences the antitumor immune response 
with increased NO associated immune suppression. Immune cells are functionally affected including the recruit-
ment and/or activation of MDSCs, Tregs, tumor-associated macrophages, and Th2 lymphocytes. Once activated, 
MDSCs also produce high amounts of NO in the tumor microenvironment, which further contributes to the inhi-
bition of antitumor responses and nitrosative stress29. It was also shown that targeting NO production may reverse 
MDSC-mediated immunosuppression by blocking inflammation-driven MDSC recruitment to the tumor30. The 
expression of iNOS in tumor cells associates with poor survival in several cancers31–33 and it is a known marker 
of chronic inflammation. Furthermore, fibroblasts express a significant amount of iNOS and this contributes to 
development of chemoresistance in pancreatic cancer cells through increased secretion of NO, which also leads 
to the release of IL-1beta by the tumor cells34. The immunosuppressive role of IL-1beta has already been shown 
in melanoma35. Our results indicate that higher iNOS expression is associated with poor T-cell effector function 
potentially limiting the effect of T cell-based immunotherapies. Multiple iNOS inhibitors have been developed36, 
and using these for the treatment of pancreatic cancer may help to prevent immune suppression and support 
adoptive T-cell therapies and cancer vaccines targeting the neoantigen landscape. Furthermore, iNOS inhibi-
tors may also serve as effective combination partners in checkpoint blockade-based therapies. As Flavopiridol, a 
pan-CDK inhibitor, has been shown to downregulate iNOS expression37, and c-Met signaling possibly acts as a 
regulator of the NF-κ B-iNOS-NO pathway38, we believe that the negative correlations between iNOS expression 
and CDK4/6 and c-MET inhibitor EC50 values indicate that iNOS plays an important role in PDAC tumor cells.
In summary, we have shown that nearly all PDAC tumors express potential targetable neoantigens which 
leads to a T-cell influx similar to immunogenic cancers like melanoma, however, an effective immune response 
cannot be generated due to a profoundly immune suppressive TME and potential immune escape. Unexpectedly, 
we found that markers of efficient antigen presentation are associated with a reduced signature of cytotoxic T 
cells, further suggesting an immune suppression mechanism that correlates with tumor antigenicity. Lastly, we 
identified high levels of immune-suppressive iNOS (NOS2) as a potential mediator of immune suppression, and 
targeting iNOS could help to augment immune response in PDAC.
Methods
Data sets. Gene expression, mutation, and clinical data from the pancreatic cancer TCGA were obtained 
from public TCGA repositories (https://tcga-data.nci.nih.gov and http://gdac.broadinstitute.org/). Raw sequenc-
ing data were requested though dbGaP (www.ncbi.nlm.nih.gov/gap) and from the authors of ICGC publica-
tions13,20. To analyze normal tissue expressions we used mRNA expression data from RNA sequencing from the 
Genotype-Tissue Expression (GTEx, http://www.gtexportal.org)22 project. CCLE cell line mRNA expression data 
were obtained from the Cancer Cell Line Encyclopedia39.
Neoantigen predictions. We predicted all possible 8–12-mer mutated neo-peptides and their respective 
HLA-binding affinities (HLA-A, -B, -C) as described earlier40. We used mutation data from pancreatic ductal ade-
nocarcinoma samples of the TCGA and ICGC20 projects. We applied the NetMHCpan (version 2.8)41 algorithm 
to predict peptide binding affinities to HLA-A, -B, and -C alleles. Patient HLA genotypes were determined from 
raw exome (normal and also tumor) and RNA sequencing data. We used the following HLA prediction tools: the 
Athlates software (version 2014_04_26)42 and the seq2HLA (version 2.2)43 program. We considered a neopeptide 
strong binder if binding affinity was < 50 nM, and weak binder if binding affinity was < 500 nM. We included both 
strong and weak binder neoantigens in our correlation analyses.
RNA sequencing data analysis. Analysis of raw RNA sequencing data was performed using the RSEM 
(version 1.2.22) software44. We used the transcripts per million (TPM) unit, which was found the most appro-
priate to compare expression results from RNA sequencing45, to analyze ICGC, TCGA, and GTEx data. Gene 
program scores were generated as previously described13.
Clustering and heatmap generation. Clustering of mRNA expression data and heatmap generation were 
performed using the Cluster and Treeview programs46.
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Other computational analyses. Pearson’s and Spearman’s rank correlation coefficients were calculated 
using the R software. Kaplan-Meier analyses were performed using the ‘survival’ R package. Comparisons of two 
groups used two-tailed Student’s t-tests assuming unequal variance. Differences were considered significant when 
p < 0.05, and a trend towards significance was shown when p < 0.1.
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